Research summary

SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA that functions as a metabolic signaling molecule.[1][2]

Remy Research materials are for in-vitro laboratory research only, not human or veterinary use.

Summary written November 14, 2026, at first publication.

Update History ▾
November 14, 2026: Initial publication, built from primary SS-31 and MOTS-c studies, FDA’s Forzinity approval announcement, Drug Trials Snapshot and prescribing information, the MMPOWER-3 trial report and ClinicalTrials.gov records checked the same day.
Research-use-only framing applied throughout in line with Remy editorial standards.
Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Preclinical studies link this interaction to preservation of cristae architecture and electron transport. It is a structural intervention at the membrane level. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA that functions as a metabolic signaling molecule, with AMPK-dependent effects and changes in nuclear gene expression under metabolic stress. One acts on mitochondrial structure; the other acts through mitochondrial signaling to reshape cellular metabolism.

The short answer: Choose SS-31 when your research centres on mitochondrial membrane integrity, oxidative phosphorylation coupling, cardiolipin biology, or ischemia–reperfusion injury models. Choose MOTS-c when your work focuses on insulin sensitivity, glucose metabolism, obesity, aging-related metabolic decline, or exercise-mimetic biology. SS-31 carries a substantially larger human evidence base. Elamipretide (Forzinity) received US FDA accelerated approval on 19 September 2025 to improve muscle strength in adults and paediatric patients with Barth syndrome weighing at least 30 kg.[3] Continued approval may depend on verification of clinical benefit in a confirmatory trial. MOTS-c remains investigational; a trial registration does not establish efficacy or safety. Neither pharmaceutical approval nor clinical safety data extend to research-grade peptides: Remy Research supplies SS-31 and MOTS-c as research-grade reagents for in-vitro use only, with no dosing, administration, or therapeutic guidance provided.

What Is SS-31 (Elamipretide) in the Context of Research?

SS-31 is a synthetic tetrapeptide (D-Arg-2ʹ,6ʹ-dimethylTyr-Lys-Phe-NH₂) engineered with alternating aromatic and cationic residues to accumulate selectively in mitochondria. SS-31 interacts with cardiolipin in the inner mitochondrial membrane, a phospholipid essential to cristae folding and ETC organisation.

Key mechanistic features relevant to laboratory researchers:

For a full review of SS-31 mechanisms, preclinical evidence and safety signals, see SS-31 Peptide Benefits, Side Effects and FDA Approval.

What Is MOTS-c for Mitochondrial and Metabolic Research?

MOTS-c is a mitochondrial-derived peptide consisting of 16 amino acids, encoded within a short open reading frame in the 12S rRNA region of mitochondrial DNA.[2] In cell experiments, MOTS-c translocates to the nucleus under metabolic stress, where it modulates nuclear gene expression involved in metabolic regulation and stress adaptation – a form of retrograde mitochondrial signaling that has attracted particular interest in aging and metabolism research.[6]

Core mechanistic properties for researchers:

For a detailed look at MOTS-c mechanisms, aging data and safety gaps, see MOTS-c Benefits and Side Effects: What Studies Show.

SS-31 vs MOTS-c: How They Compare at a Glance

The table below is a quick reference for labs deciding which peptide aligns with a given research question. Both peptides represent distinct areas of mitochondrial research. The research-fit judgments below are based on their mechanisms and published models, not a direct comparative trial.

Factor SS-31 (Elamipretide) MOTS-c
Compound identity Synthetic tetrapeptide (4 aa), D-Arg-dimethylTyr-Lys-Phe-NH₂ Mitochondrial-derived peptide (16 aa), encoded in the mtDNA 12S rRNA region
Primary target / mechanism Cardiolipin in the inner mitochondrial membrane; effects on membrane architecture and electron transport AMPK-dependent metabolic signaling and stress-responsive nuclear gene expression
Best-suited research focus Mitochondrial membrane bioenergetics, cardiolipin biology, ATP coupling, ischemia–reperfusion injury Insulin resistance, obesity, exercise signaling, metabolic adaptation
Clinical development Forzinity has a specific US accelerated approval; the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary endpoints No MOTS-c treatment trial with posted results at review; the CB4211 analogue completed a Phase 1a/1b study
Human evidence base Randomised trials include SPIBA-201 (12 patients) and MMPOWER-3 (218 patients); results differ by indication Endogenous-level studies; no interventional trial with posted results at review; CB4211 analogue evidence must be assessed separately
Safety profile Injection-site reactions are common; serious hypersensitivity is a labelled risk Human safety remains insufficiently characterised
Regulatory status Forzinity: US accelerated approval to improve muscle strength in Barth syndrome adult and paediatric patients weighing at least 30 kg; this does not establish UAE/GCC authorisation Investigational; trial registration is not marketing approval
Example experimental models Aged mouse skeletal muscle; renal ischemia–reperfusion Diet-induced obesity and insulin resistance in mice; stressed cell cultures; neuropathic pain models

Both peptides are studied in mitochondrial biology but through different mechanisms: SS-31 acts at the mitochondrial membrane, while MOTS-c is involved in metabolic signaling and cellular adaptation.

Decisive Factor 1: Mechanism and Site of Action

Mechanistic fit is usually the main driver when choosing between these peptides for laboratory research. The published literature includes cell and animal experiments; Remy Research reagents are supplied for in-vitro use only. The two compounds operate at fundamentally different biological levels, and matching your tool to your question matters more than any other consideration.

SS-31:

MOTS-c:

Implications for experimental design:

Winner: Mechanistic specificity depends on the question. SS-31 wins for direct mitochondrial membrane and cardiolipin-focused studies. MOTS-c wins for systemic metabolic signaling questions. This makes the winner conditional rather than universal – a reflection of the distinct mechanisms these peptides employ.

Decisive Factor 2: Human vs Animal/In-Vitro Evidence

Lab buyers planning translational work often want to know where robust human data exist – even if their own experiments are preclinical. The gap here is substantial.

SS-31 (elamipretide) evidence trajectory:

Human clinical data include multiple randomised trials. In Barth syndrome, SPIBA-201 began with a 12-patient randomised crossover period. Neither the 6-minute walk distance nor fatigue co-primary endpoint showed superiority at 12 weeks. Ten patients entered the open-label extension, which continued for up to 192 weeks. Improvements in knee-extensor strength during open-label follow-up supported accelerated approval; this uncontrolled result does not carry the same evidential weight as a positive placebo-controlled outcome.[10] A confirmatory trial is required to verify clinical benefit.[3]

In primary mitochondrial myopathy, MMPOWER-3 randomised 218 patients and found no significant improvement over placebo in either 6-minute walk distance or fatigue at 24 weeks.[11] The Barth syndrome approval should not be generalised to other mitochondrial disorders.

Preclinical work includes improvements in exercise tolerance, skeletal-muscle bioenergetics and redox balance in aged mice, and protection in renal ischemia–reperfusion models.[4][5] These findings support mechanistic research, not claims of proven human anti-aging or exercise benefits.

MOTS-c evidence:

Much of the MOTS-c evidence comes from rodent models of diet-induced obesity, insulin resistance and aging. In cell culture, a study of aged human placenta-derived mesenchymal stem cells reported improved mitochondrial homeostasis with reduced reactive oxygen species and altered lipid metabolism.[12] These results are specific to the experimental cells and conditions.

Published human physiological studies measure endogenous MOTS-c. In lipid-infusion experiments, circulating levels rose to approximately 232% of baseline in controls and 349% in women with polycystic ovary syndrome — about 2.3 and 3.5 times baseline, respectively.[13] The exercise study cited above reported a trend for MOTS-c, not a statistically significant increase. Neither study tested MOTS-c as a treatment.

Interventional research on native MOTS-c has not yet reported results. A ClinicalTrials.gov search on 14 November 2026 found no MOTS-c treatment trial with posted results, and a registry entry by itself does not establish efficacy or safety. Separately, NCT03998514 is a completed Phase 1a/1b study of CB4211 in 88 participants.[8] The developer identifies CB4211 as a MOTS-c analogue; findings for that compound cannot be treated as results for native MOTS-c.[14]

No published head-to-head SS-31 vs MOTS-c human trial was identified in the sources reviewed. The comparison here is indirect.

Winner: SS-31. SS-31 has more extensive human trial data and a defined approved indication, making it the stronger reference where translation to human pathophysiology is a priority. MOTS-c remains at an earlier stage, with most supporting findings still preclinical and no interventional trial results available.

Decisive Factor 3: Safety Signals and Research Limitations

Safety data for these peptides come from formal elamipretide clinical trials and early MOTS-c preclinical studies – not from uncontrolled use of research-grade reagents.

SS-31 / elamipretide safety:

Published trial data and the FDA prescribing information for Forzinity report:[15]

MOTS-c safety:

Boundary statement: Remy Research products are labelled “for research use only.” No safety should be inferred for self-administration or clinical use from their provision as reagents. No dosing, route of administration, cycle length, or stacking advice is given. For more on research-grade peptide sourcing, see Peptide Supplier Checklist: What to Record.

Winner: SS-31 for better-characterised safety, not proven superior safety. Elamipretide has a characterised safety profile in defined patients and trials. MOTS-c remains less characterised, with greater unknowns. Neither status should be extrapolated to unsupervised use of research-grade material.

Decisive Factor 4: Practical Use in Laboratory Models

Beyond mechanism and evidence, practical considerations – which assays, which tissues, which readouts – often determine which peptide a lab should procure.

SS-31:

MOTS-c:

Practical notes for both:

Winner: Depends on experimental endpoint. SS-31 is usually the stronger choice for mechanistic mitochondrial bioenergetics – membrane structure, electron transport, oxidative damage, and recovery from acute injury. MOTS-c is better for systemic metabolic phenotypes – glucose metabolism, body composition, exercise biology. Match peptide to primary endpoint rather than trend.

SS-31 vs MOTS-c: Which Should Your Lab Choose?

There is no universal “better” peptide in mitochondrial medicine research – only a better fit for a given hypothesis. The comparison above consistently shows that these compounds operate through distinct mechanisms at different biological levels, with different evidence maturity.

While some online sources speculate about combining SS-31 and MOTS-c, no published controlled combination human trial was identified in the sources reviewed. Synergy claims remain unproven hypotheses. Laboratory interaction studies need appropriate factorial controls.

Remy Research supplies research-grade SS-31 and MOTS-c for in-vitro use only, not for human or veterinary administration. Published animal studies discussed here do not change that product-use boundary.

Our Research Standards

This comparison prioritizes primary literature, trial registries and regulator records, and keeps cell, animal and human evidence apart. Where the human record is empty, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

Frequently Asked Questions About SS-31 vs MOTS-c

These address common research planning questions – not clinical decision-making or self-experimentation.

Can SS-31 and MOTS-c be used together in the same experiment?

Co-exposure can be investigated in vitro with appropriate controls. The sources reviewed do not establish a validated combination protocol from human data. Researchers should design factorial experiments (SS-31 alone, MOTS-c alone, both, and vehicle controls) to test interaction effects rather than assume synergy. No advice is given on co-administration in humans or animals outside controlled research protocols.

Is SS-31 safer or more “proven” than MOTS-c for human use?

Elamipretide has undergone formal clinical testing and achieved US accelerated approval in a specific ultra-rare disease (Barth syndrome), so its safety profile is more characterised than that of MOTS-c. This does not mean SS-31 is “safe” for off-label or unsupervised use – especially not in the form of research-grade reagents. MOTS-c remains investigational with much less human data; unknowns are greater. Remy Research does not make or support any therapeutic safety claims for either peptide.

Are SS-31 or MOTS-c approved for clinical use in the UAE or GCC?

Regulatory approvals are jurisdiction-specific. US FDA decisions do not automatically apply to the UAE, Saudi Arabia or other GCC markets. The verified US approval is Forzinity’s specific accelerated approval for muscle strength in Barth syndrome patients weighing at least 30 kg. This review has not established current UAE or other GCC marketing authorisations for either compound; local status must be checked with the relevant regulator. Trial registration and availability from a research supplier do not establish clinical approval. Remy Research supplies research-use-only reagents.

Where can I find deeper, compound-specific reviews of SS-31 and MOTS-c?

Remy Research’s Peptide Research Library includes detailed posts on both compounds:

For the most current data, consult primary literature, clinical trial registries (e.g. ClinicalTrials.gov), and regulatory assessment reports directly.

Sources

  1. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-2028. doi: 10.1111/bph.12468 · PMID: 24134698 ↩
  2. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009 · PMID: 25738459 ↩
  3. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Press announcement, September 19, 2025. fda.gov ↩
  4. Campbell MD, Duan J, Samuelson AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. doi: 10.1016/j.freeradbiomed.2018.12.031 · PMID: 30597195 ↩
  5. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8). doi: 10.1681/ASN.2012121216 · PMID: 23813215 ↩
  6. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. doi: 10.1016/j.cmet.2018.06.008 · PMID: 29983246 ↩
  7. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3). doi: 10.1152/japplphysiol.00706.2019 · PMID: 34351816 ↩
  8. ClinicalTrials.gov. NCT03998514, Phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with NAFLD (completed; 88 enrolled; record checked November 14, 2026). clinicaltrials.gov/study/NCT03998514 ↩
  9. Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026;246:682-696. doi: 10.1016/j.freeradbiomed.2026.01.002 ↩
  10. U.S. Food and Drug Administration. Drug Trials Snapshots: Forzinity (SPIBA-201; approval date September 19, 2025). fda.gov ↩
  11. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3). doi: 10.1212/WNL.0000000000207402 · PMID: 37268435 ↩
  12. Yu WD, Kim YJ, Cho MJ, et al. The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells in vitro. Mitochondrion. 2021;58:135-146. doi: 10.1016/j.mito.2021.02.010 ↩
  13. Ramanjaneya M, Jerobin J, Bettahi I, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). 2019;91(2). doi: 10.1111/cen.14007 · PMID: 31066084 ↩
  14. CohBar, Inc. Press release dated November 5, 2018 (Form 8-K, Exhibit 99.1): CB4211 described as an analog of MOTS-c. sec.gov ↩
  15. Stealth BioTherapeutics Inc. FORZINITY (elamipretide) injection, prescribing information, 2025. accessdata.fda.gov ↩
  16. Jiang J, Xu L, Yang L, Liu S, Wang Z. Mitochondrial-derived peptide MOTS-c ameliorates spared nerve injury-induced neuropathic pain in mice by inhibiting microglia activation and neuronal oxidative damage in the spinal cord via the AMPK pathway. ACS Chem Neurosci. 2023;14(12). doi: 10.1021/acschemneuro.3c00140 · PMID: 37285113 ↩

For catalog details, see the SS-31 40mg pen and the MOTS-c 10mg research vial. For editorial standards, continue to the editorial policy.